The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Open accessAbstract
Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, which led to the limitation of clinical application. Motivated by potent and durable efficacy of ICIs, oncologists endeavor to explore the mechanisms of resistance to ICIs and increase the drug sensitivity. It is known that heterogeneity of gut microbiome in populations may result in different outcomes of therapy. In xenograft model, bacteria in gut have been proved as a crucial factor regulating immunotherapy efficacy. And the similar phenomenon was obtained in patients. In this review, we summarized relevant advancements about gut microbiome and ICIs. Furthermore, we focused on modulatory function of gut microbiome in ICIs therapy and possible antitumor mechanism of specific commensals in ICIs treatment. We propose that gut microbiome is an important predictive factor, and manipulation of gut microbiome is feasible to elevate response rate in ICIs therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some gut bacteria act as suppressors of inhibitory signal pathways, facilitate antigen presentation, and improve specific antitumor immunity (118).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [118]
In the citing paper
“In conclusion, in view of the metabolic function elicited by gut microbiota, we infer that their metabolic byproducts are perceived by cells and molecules of the immune system and modulate the equilibrium between pro- and antitumor functions.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [118]
In the citing paper
“The influence of gut microbiota on host immunity is multifaceted, simultaneously regulating the gut mucosal immune system and systemic immune system (Fig. 2d) [307–310].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [308]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 15×
“The fecal microbiome transplantation in mice supported the conclusions aforementioned [11].”
BackgroundMethodResultInfluentialSokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., Blugeon, S., Bridonneau, C., Furet, J.-P., Corthier, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804812105 · Cited by 4,413
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 8×
“lymphocytes recruitment, more potent neoantigen presentation process and cytokines production [68].”
BackgroundInfluentialInduction of Colonic Regulatory T Cells by Indigenous Clostridium Species
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., et al. (2011) · Science · doi:10.1126/science.1198469 · Cited by 3,752
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 13×
“uniformis) was accompanied with the decrease of Bacteroidales and Burkholderiales (Table 1) [70].”
BackgroundInfluentialThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 10×
“Parabacteroides merdae Human a) Related with enhanced efficacy of PD-1 blockade b) Leading to decreased peripherally derived Treg Matson V 2018 [69]”
BackgroundInfluentialAn Immunomodulatory Molecule of Symbiotic Bacteria Directs Maturation of the Host Immune System
Mazmanian, S. K., Liu, C. H., Tzianabos, A. O., & Kasper, D. L. (2005) · Cell · doi:10.1016/j.cell.2005.05.007 · Cited by 2,910
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725
Role of the gut microbiota in immunity and inflammatory disease
Kamada, N., Seo, S.-U., Chen, G. Y., & Núñez, G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3430 · Cited by 2,256
Shotgun metagenomics, from sampling to analysis
Quince, C., Walker, A. W., Simpson, J. T., Loman, N. J., & Segata, N. (2017) · Nature Biotechnology · doi:10.1038/nbt.3935 · Cited by 2,202
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon
Donohoe, D. R., Garge, N., Zhang, X., Sun, W., O'Connell, T. M., Bunger, M. K., & Bultman, S. J. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.018 · Cited by 2,003 · cited 1×
“bacterial metabolites, such as SCFAs, can be utilized by intestinal epithelial cells as source of energy [97, 98].”
BackgroundCTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Innate immunity and intestinal microbiota in the development of Type 1 diabetes
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., et al. (2008) · Nature · doi:10.1038/nature07336 · Cited by 1,921
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Microbes in Gastrointestinal Health and Disease
Neish, A. S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.10.080 · Cited by 1,423
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
T cell metabolism drives immunity
Buck, M. D., O’Sullivan, D., & Pearce, E. L. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20151159 · Cited by 1,238
CTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
Induction and molecular signature of pathogenic TH17 cells
Lee, Y., Awasthi, A., Yosef, N., Quintana, F. J., Xiao, S., Peters, A., Wu, C., Kleinewietfeld, M., Kunder, S., Hafler, D. A., et al. (2012) · Nature Immunology · doi:10.1038/ni.2416 · Cited by 1,174
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 971
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970
Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968
Commensal bacteria at the interface of host metabolism and the immune system
Brestoff, J. R., & Artis, D. (2013) · Nature Immunology · doi:10.1038/ni.2640 · Cited by 945
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 939
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898
Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897
Microbiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858
Microbes, Microbiota, and Colon Cancer
Sears, C. L., & Garrett, W. S. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.007 · Cited by 853
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Antibiotic use and its consequences for the normal microbiome
Blaser, M. J. (2016) · Science · doi:10.1126/science.aad9358 · Cited by 836
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature reviews. Immunology · doi:10.1038/nri3108 · Cited by 817
Human Gut Microbiome: Function Matters
Heintz‐Buschart, A., & Wilmes, P. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.11.002 · Cited by 779
Tlaskalová‐Hogenová, H., Štëpánková, R., Hudcovic, T., Tučková, L., Cukrowská, B., Lodinová‐Žádníková, R., Kozáková, H., Rossmann, P., Bártová, J., Sokol, D., et al. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.02.005 · Cited by 755
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 649
Holmgaard, R., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 646
Resistance to PD1/PDL1 checkpoint inhibition
O’Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 587
Gut Microbiota, Inflammation, and Colorectal Cancer
Brennan, C. A., & Garrett, W. S. (2016) · Annual Review of Microbiology · doi:10.1146/annurev-micro-102215-095513 · Cited by 586
Anticancer effects of the microbiome and its products
Zitvogel, L., Daillère, R., Roberti, M. P., Routy, B., & Kroemer, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.44 · Cited by 538
Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529
An enteric virus can replace the beneficial function of commensal bacteria
Kernbauer, E., Ding, Y., & Cadwell, K. (2014) · Nature · doi:10.1038/nature13960 · Cited by 527
Hirota, K., Turner, J.-E., Villa, M., Duarte, J. H., Demengeot, J., Steinmetz, O. M., & Stockinger, B. (2013) · Nature Immunology · doi:10.1038/ni.2552 · Cited by 509
The microbiome and rheumatoid arthritis
Scher, J. U., & Abramson, S. B. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.121 · Cited by 493
Cancer and the gut microbiota: An unexpected link
Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., & Kroemer, G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010473 · Cited by 465
Immunological Consequences of Intestinal Fungal Dysbiosis
Wheeler, M. L., Limon, J. J., Bar, A. S., Leal, C. A., Gargus, M. D., Tang, J., Brown, J. S., Funari, V. A., Wang, H. L., Crother, T. R., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.05.003 · Cited by 427
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 387
Mouse models in oncoimmunology
Zitvogel, L., Pitt, J. M., Daillère, R., Smyth, M. J., & Kroemer, G. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.91 · Cited by 361
Ecological Physiology of Diet and Digestive Systems
Karasov, W. H., del Rio, C. M., & Caviedes‐Vidal, E. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142152 · Cited by 359
Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism
Mao, K., Baptista, A. P., Tamoutounour, S., Zhuang, L., Bouladoux, N. J., Martins, A. J., Huang, Y., Gerner, M. Y., Belkaid, Y., & Germain, R. N. (2018) · Nature · doi:10.1038/nature25437 · Cited by 357
Microbiome-modulated metabolites at the interface of host immunity
Blacher, E., Levy, M., Tatirovsky, E., & Elinav, E. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601247 · Cited by 354
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K. M., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 346
Ma, W., Gilligan, B. M., Yuan, J. D., & Li, T. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0277-y · Cited by 333
Kythreotou, A., Siddique, A., Mauri, F. A., Bower, M., & Pinato, D. J. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204853 · Cited by 333
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 318
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 314
Self-citationMicrobiota, Disease, and Back to Health: A Metastable Journey
Blumberg, R. S., & Powrie, F. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004184 · Cited by 287
The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity
Tai, N., Wong, F. S., & Li, W. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9309-0 · Cited by 260
Haanen, J. B. A. G., & Robert, C. (2015) · Progress in tumor research · doi:10.1159/000437178 · Cited by 221
Resurrection of endogenous retroviruses in antibody-deficient mice
Young, G. R., Eksmond, U., Salcedo, R., Alexopoulou, L., Stoye, J. P., & Kassiotis, G. (2012) · Nature · doi:10.1038/nature11599 · Cited by 215
Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
Boussiotis, V. A., Chatterjee, P., & Li, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000059 · Cited by 190
Anti‐CD73 therapy impairs tumor angiogenesis
Allard, B., Turcotte, M., Spring, K., Pommey, S., Royal, I., & Stagg, J. (2013) · International Journal of Cancer · doi:10.1002/ijc.28456 · Cited by 171
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
Peters, S., Kerr, K. M., & Stahel, R. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.002 · Cited by 160
Recent advances of bispecific antibodies in solid tumors
Yu, S., Li, A., Liu, Q., Yuan, X., Xu, H., Jiao, D., Pestell, R. G., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0522-z · Cited by 152
Self-citationMullins, I. M., Slingluff, C. L., Lee, J. K., Garbee, C. F., Shu, J., Anderson, S. G., Mayer, M. E., Knaus, W. A., & Mullins, D. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2059 · Cited by 150
Terp, M. G., Olesen, K. A., Arnspang, E. C., Lund, R. R., Lagerholm, B. C., Ditzel, H. J., & Leth‐Larsen, R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301274 · Cited by 141
Checkpoint inhibitors in hematological malignancies
Ok, C. Y., & Young, K. H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0474-3 · Cited by 139
The microbiome and hepatobiliary-pancreatic cancers
Mima, K., Nakagawa, S., Sawayama, H., Ishimoto, T., Imai, K., Iwatsuki, M., Hashimoto, D., Baba, Y., Yamashita, Y., Yoshida, N., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.001 · Cited by 136
The microbiome and its potential as a cancer preventive intervention
Bultman, S. J. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.001 · Cited by 134
Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
Pitt, J. M., Vétizou, M., Waldschmitt, N., Kroemer, G., Chamaillard, M., Boneca, I. G., & Zitvogel, L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0448 · Cited by 122
Long, J., Lin, J., Wang, A., Wu, L., Zheng, Y., Yang, X., Wan, X., Xu, H., Chen, S., & Zhao, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0511-2 · Cited by 115
Self-citationPD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
Wang, J., Yuan, R., Song, W., Sun, J., Liu, D., & Li, Z. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0403-5 · Cited by 111
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
Wang, G. X., Kurra, V., Gainor, J. F., Sullivan, R. J., Flaherty, K. T., Lee, S. I., & Fintelmann, F. J. (2017) · Radiographics · doi:10.1148/rg.2017170085 · Cited by 107
Dietary Modification of the Intestinal Microbiota
Mai, V. (2004) · Nutrition Reviews · doi:10.1111/j.1753-4887.2004.tb00045.x · Cited by 89
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy
Spranger, S., Sivan, A., Corrales, L. P., & Gajewski, T. F. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.003 · Cited by 87
Clinical applications of PD-L1 bioassays for cancer immunotherapy
Liu, D., Wang, S., & Bindeman, W. E. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0479-y · Cited by 86
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma
Jacquelot, N., Enot, D. P., Flament, C., Vimond, N., Blattner, C., Pitt, J. M., Yamazaki, T., Roberti, M. P., Daillère, R., Vétizou, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80071 · Cited by 79
Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis
Wang, L., Tang, S., Wang, Y., Xu, S., Yu, J., Zhi, X., Ou, Z., Yang, J., Zhou, P., & Shao, Z. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9571-z · Cited by 75
Gastrointestinal Microbiota and Colon Cancer
Hold, G. L. (2016) · Digestive Diseases · doi:10.1159/000443358 · Cited by 75
Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13081 · Cited by 72
The Multibiome: The Intestinal Ecosystem's Influence on Immune Homeostasis, Health, and Disease
Filyk, H. A., & Osborne, L. C. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.007 · Cited by 71
Hefazi, M., Patnaik, M. M., Hogan, W. J., Litzow, M. R., Pardi, D. S., & Khanna, S. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.08.016 · Cited by 66
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Liu, S. M., & Wu, Y.-L. L. C. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0506-z · Cited by 63
Botticelli, A., Zizzari, I. G., Mazzuca, F., Ascierto, P. A., Putignani, L., Marchetti, L., Napoletano, C., Nuti, M., & Marchetti, P. (2016) · Oncotarget · doi:10.18632/oncotarget.12985 · Cited by 57
Human Microbiome Acquisition and Bioinformatic Challenges in Metagenomic Studies
D’Argenio, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020383 · Cited by 56
Immunotherapy Not Working? Check Your Microbiota
West, N. R., & Powrie, F. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.010 · Cited by 55
A Transendocytosis Perspective on the CD28/CTLA-4 Pathway
Soskic, B., Qureshi, O. S., Hou, T., & Sansom, D. M. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800147-9.00004-2 · Cited by 43
Goel, G., & Sun, W. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0185-6 · Cited by 32
Dietary Modification of the Intestinal Microbiota
Mai, V. (2004) · Nutrition Reviews · doi:10.1301/nr2004.jun235-242 · Cited by 32
Carpenter, M. R., Rozovsky, S., & Boyd, E. F. (2015) · Journal of Bacteriology · doi:10.1128/jb.00704-15 · Cited by 27
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
Carbonnel, F., Soularue, É., Coutzac, C., Chaput, N., Mateus, C., Lepage, P., & Robert, C. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-016-0613-x · Cited by 26
Ozaki, Y., Shindoh, J., Miura, Y., Nakajima, H., Oki, R., Uchiyama, M., Masuda, J., Kinowaki, K., Kondoh, C. N., Tanabe, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3785-4 · Cited by 25
Microbiote intestinal et réponses aux thérapies anti-tumorales
Vétizou, M., Daillère, R., & Zitvogel, L. (2016) · médecine/sciences · doi:10.1051/medsci/20163211013 · Cited by 21
Irrazábal, T., & Martín, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0987 · Cited by 13
The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Lu, J., & Ramirez, R. A. (2017) · PubMed Central · Cited by 9
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Self-citationNovel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
Self-citationBiomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
Self-citationRegulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Self-citationRNA sequencing: new technologies and applications in cancer research
Hong, M., Tao, S., Zhang, L., Diao, L., Huang, X., Huang, S., Xie, S., Xiao, Z., & Zhang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01005-x · Cited by 626
Metadata
- Authors
- Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K.
- Affiliations
- Tongji Hospital (CN)
- Corresponding author
- Chu, Qian
- Wu, Kongming
- Venue
- Journal of Hematology & Oncology
- Published
- 2018-03-27
- Volume
- 11
- Issue
- 1
- Pages
- 47-47
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC5870075
- OpenAlex
- W2794616539
- Cited by
- 179
- References
- 110
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 17 · 2023: 23 · 2022: 32 · 2021: 26 · 2020: 24 · 2019: 26 · 2018: 10
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81572608 and 81172422, 81672984)
- Wuhan Science and Technology Bureau (2017060201010170)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, immune checkpoint inhibitors, immunotherapy efficacy, cancer immunotherapy, treatment resistance, predictive biomarkers, commensal bacteria, anticancer mechanism, microbiome manipulation
- MeSH terms
- Gastrointestinal Microbiome, Humans, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
